白細(xì)胞減少癥是化療常見的不良反應(yīng)，目前已知的治療手段有限、不良反應(yīng)多，急需尋找新的有效的治療手段。中醫(yī)學(xué)將白細(xì)胞減少癥歸為“血虛”“氣虛”，近年來研究發(fā)現(xiàn)，中藥及其活性成分具有良好的造血功效，且具有安全性高、不良反應(yīng)小等優(yōu)點(diǎn)，能有效提升白細(xì)胞并改善相關(guān)癥狀，中藥復(fù)方也顯示出良好療效。對中藥及其活性成分改善白細(xì)胞減少癥的作用及機(jī)制研究現(xiàn)狀進(jìn)行綜述，為治療白細(xì)胞減少癥藥物的進(jìn)一步研發(fā)提供理論依據(jù)。

Leukopenia is a common side effect of chemotherapy, and there is an urgent need to find new and effective treatments for it, as the known treatments are limited and have many side effects. In Chinese medicine, leukopenia is classified as "blood deficiency" and "qi deficiency". Recent studies have found that traditional Chinese medicine (TCM) and its active ingredients have good hematopoietic effects, as well as benefits such as high safety and minimal side effects. They can effectively increase the white blood cell count and improve the associated symptoms, and TCM formulas have also shown good therapeutic effects. This article summarizes the effects and mechanisms of TCM and its active ingredients in treating leukopenia, as well as a theoretical basis for future studies and drug development for leukopenia.

R285

上海市衛(wèi)生健康委員會中醫(yī)藥科研項(xiàng)目（2024QN057）；軍隊(duì)后勤科研項(xiàng)目（BHJ22J020）；海軍重點(diǎn)學(xué)科專業(yè)群建設(shè)項(xiàng)目（2024-HJZDXK-JS-12，2024-HJZDXK-SZ-01）；國家重點(diǎn)研發(fā)計(jì)劃（2022YFC3502000）；國家自然科學(xué)基金項(xiàng)目（82430119，82173704）；海軍軍醫(yī)大學(xué)“深藍(lán)”工程啟航人才計(jì)劃；海軍軍醫(yī)大學(xué)教學(xué)成果立項(xiàng)培育項(xiàng)目（JPY2024B06）；海軍軍醫(yī)大學(xué)藥學(xué)系“雛鷹”學(xué)員課題